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ABSTRACT
OBJECTIVE: To investigate the factors related to the granting of preliminary 
court orders [injunctions] in drug litigations.
METHODS: A retrospective descriptive study of drug lawsuits in the State 
of Minas Gerais, Southeastern Brazil, was conducted from October 1999 to 
2009. The database consists of 6,112 lawsuits, out of which 6,044 had motions 
for injunctions and 5,167 included the requisition of drugs. Those with more 
than one beneficiary were excluded, which totaled 5,072 examined suits. 
The variables for complete, partial, and suppressed motions were treated as 
dependent and assessed in relation to those that were independent – lawsuits 
(year, type, legal representation, defendant, court in which it was filed, 
adjudication time), drugs (level five of the anatomical therapeutic chemical 
classification), and diseases (chapter of the International Classification of 
Diseases). Statistical analyses were performed using the Chi-square test.
RESULTS: Out of the 5,072 lawsuits with injunctions, 4,184 (82.5%) had the 
injunctions granted. Granting varied from 95.8% of the total lawsuits in 2004 
to 76.9% in 2008. Where there was legal representation, granting exceeded 
80.0% and in lawsuits without representation, it did not exceed 66.9%. In 
public civil actions (89.1%), granting was higher relative to ordinary lawsuits 
(82.8%) and injunctions (80.1%). Federal courts granted only 68.6% of the 
injunctions, while the state courts granted 84.8%. Diseases of the digestive 
system and neoplasms received up to 87.0% in granting, while diseases of 
the nervous system, mental and behavioral disorders, and diseases of the 
skin and subcutaneous tissue received granting below 78.6% and showed 
a high proportion of suspended injunctions (10.9%). Injunctions involving 
paroxetine, somatropin, and ferrous sulfate drugs were all granted, while 
less than 54.0% of those involving escitalopram, sodium diclofenac, and 
nortriptyline were granted.
CONCLUSIONS: There are significant differences in the granting of 
injunctions, depending on the procedural and clinical variances. Important 
trends in the pattern of judicial action were observed, particularly, in the 
reduced granting [of injunctions] over the period.
DESCRIPTORS: Pharmaceutical Preparations, supply & distribution. 
Pharmaceutical Services, legislation & jurisprudence. Judicial 
Decisions. Patient Advocacy.
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Defining the judiciary’s role is one of the greatest chal-
lenges of democratic societies. It is a difficult and contro-
versial task to identify the limits of judicial activity, espe-
cially in its control over political activity.2,5,7 This task 
has become increasingly more intricate due to the proac-
tiveness of the judiciary in guaranteeing the efficacy of 
social rights. This new position has expanded the hori-
zons of judicial action, reconfigured relations between 
the different branches of government, and destabilized 
the structures that once served to steer the checks and 
balances system in the judiciary.12,a
Judicial proactivity in Brazil has gained prominence 
in the healthcare industry. Over 240,000 lawsuits 
RESUMO
OBJETIVO: Investigar fatores relacionados ao deferimento de liminares por 
medicamentos.
MÉTODOS: Estudo descritivo retrospectivo dos processos judiciais por 
medicamentos em Minas Gerais, de outubro de 1999 a 2009. A base de dados, 
constituída por 6.112 ações judiciais, teve 6.044 com pedido de liminar e 5.167 
com requisição de medicamentos. Foram excluídas as ações que continham mais 
de um beneficiário, totalizando 5.072 ações analisadas. As variáveis deferimento 
total, parcial e suspensão foram tratadas como dependentes e avaliadas em relação 
às independentes: processo (ano, tipo de ação, representação judicial, réu, justiça 
de ajuizamento, tempo de decisão judicial), medicamentos (nível 5 da Anatomical 
Therapeutic Chemical) e doença (por capítulo da Classificação Internacional de 
Doenças. As análises estatísticas foram realizadas pelo teste Qui-quadrado.
RESULTADOS: Dentre as 5.072 ações com liminares, 4.184 (82,5%) foram 
deferidas. O deferimento variou de 95,8% em 2004 a 76,9% em 2008. Quando houve 
representação judicial, o deferimento superou 80,0%; nas ações sem representação, 
não ultrapassou 66,9%. Nas ações civis públicas (89,1%) o deferimento foi superior 
ao verificado em ações ordinárias (82,8%) e nos mandados de segurança (80,1%). A 
Justiça Federal deferiu apenas 68,6% das liminares, contra 84,8% da Justiça Estadual. 
Doenças do aparelho digestivo e neoplasias apresentaram deferimento acima de 
87,0%, enquanto doenças do sistema nervoso, transtornos mentais e comportamentais 
e doenças da pele e do tecido celular subcutâneo tiveram deferimento inferior a 78,6% 
e apresentaram elevada proporção de liminares suspensas (10,9%). Os fármacos 
paroxetina, somatropina e sulfato ferroso tiveram 100% de deferimento. Escitalopram, 
diclofenaco de sódio e nortriptilina obtiveram deferimento inferior a 54,0%.
CONCLUSÕES: Há diferença significativa no deferimento das liminares a partir de 
variáveis processuais e clínicas. Tendências importantes no padrão de atuação judicial 
foram observadas, particularmente a redução do deferimento ao longo do período.
DESCRITORES: Preparações Farmacêuticas, provisão & distribuição. 
Assistência Farmacêutica, legislação & jurisprudência. Decisões Judiciais. 
Defesa do Paciente.
INTRODUCTION
for health benefits were in progress in 2011, which 
contributes to the exponential growth of expenditure 
and indicates that the judiciary is determined to play 
a prominent role in the process of guaranteeing the 
right to health.
Petitioning for medicines via the judiciary represents 
the principal means by which the constitutional right 
to health is exercised. Consequently, this method 
presents itself as one of the factors that can influence 
the interpretation of the National Policy on Drugs. The 
change in the performance of pharmaceutical assis-
tance for the implementation of this policy was recently 
directed to the expanding of the concept of essential 
a Cappelletti M. Juízes legisladores? Porto Alegre: Fabris; 1993.
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drugs, culminating in the inclusion of several drugs in 
the essential drugs list in force (RENAME – 2013) in 
order to universalize the availability of drugs according 
to growing demands.b,c,d
Because of this major role, several issues arise, 
which control the effects of judicial intervention. 
While the judiciary is appointed as the last resort for 
those who do not receive the necessary health care 
guaranteed by the State, judicial action often has 
negative effects on the development of the health 
system (e.g., irrational spending) and may eventually 
harm patients seeking legal protection (e.g., cases 
of lawsuits that determine the delivery of multiple 
drugs whose combined use results in drug interac-
tions, causing adverse reactions and endangering 
patients’ health).3,4,9,13
Injunction motions are among the key aspects of this 
phenomenon. Under Article 273 of the Code of Civil 
Procedure, this procedural tool seeks to anticipate the 
motion made in court, where delaying the verdict can 
jeopardize the right being claimed. Thus, the granting 
of injunction does not require a definitive proof of the 
existence of a right, but requires the plaintiff to prove 
that the delay in deciding endangers the right being 
claimed (periculum in mora).
In case of legalization of health, this application is very 
common, and most of the suits receive favorable deci-
sion. The high rate of granting has been problematized 
in several studies and concludes by questioning the 
limits to use such an instrument in suits, which seeks 
access to medicines.6,8 It is important to acknowledge 
that injunctions may be essential to ensure a patient’s 
right to an emergency situation. However, some features 
of this procedural tool – urgency, plausibility of the 
claims, and provisional decision – can be decisive in 
the disorganization of the health system and increasing 
the use of drugs without sufficiently documented scien-
tific evidence.3
Despite emphasizing the injunction motions in inves-
tigations dealing with the legalization of health, espe-
cially with regard to the developments in drug policy 
management and to promote rational use of granting, 
one cannot find studies with a specific approach on the 
use of this procedural tool [injunction] in drug suits.e 
This absence precludes an understanding of the funda-
mentals that guide the magistrate in the decision-
making process of the injunctions and prevents him/
her from reaching further clarity about the balanced 
use of such an instrument.
This study aims to investigate the factors related to 
granted injunctions in the health care industry.
METHODS
A retrospective descriptive study based on the data 
obtained from administrative files related to lawsuits for 
drugs in the state of Minas Gerais, Southeastern Brazil, 
was conducted from 1999 to 2009 October.
Data were collected from the personnel of the State 
Secretariat of Health of Minas Gerais, between 
February and November 2009, by researchers of the 
Grupo de Pesquisa em Economia da Saúde (GPES – 
Health Economics Research Group) of Universidade 
Federal de Minas Gerais (UFMG). A pretested ques-
tionnaire, on completed or ongoing court proceed-
ings, was presented to the administrative personnel. 
The information obtained was stored in a database 
by using Microsoft Office Access 2007®, including 
6,112 lawsuits in total. Among these, 6,044 had 
motions for injunction filed and 5,167 were petitions 
for drugs. Cases with more than one beneficiary were 
excluded because of the difficulty to establish unam-
biguous association in those with more than one patient, 
and consequently, several drugs. During screening, 
5,072 cases (83.0% in total) were selected with refer-
ence to 6,237 diseases and 9,932 drugs.
Associations for the descriptive analysis were estab-
lished using database management system (DBMS) 
MySQL 5.1.41, and the rest of the primary analyses 
were performed using Microsoft Office Excel 2007®.
The dichotomous variables related to total, partial, and 
suppressed injunctions were treated as dependent. Due 
to the unknown distribution of each variable, Pearson’s 
Chi-squared test was performed with Yates continuity 
correction (p < 0.05), reporting only the statistically 
significant variables. Independent variables were 
described in terms of the distribution of relative and 
absolute frequency. Independent variables were the 
beneficiary (gender, legal representative), case (year, 
type of lawsuit, legal representation, defendant, type 
of court filed with, time of adjudication, the district of 
prosecution, judiciary department), drugs by chemical 
substance pursuant to level five of the Anatomical 
Therapeutic Chemical (ATC), disease (according 
b Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Política nacional de medicamentos. Brasília (DF); 2001.
c Decreto nº 7.508, de 28 de junho de 2011. Regulamenta a Lei nº 8.080, de 19 de setembro de 1990, para dispor sobre a organização do 
Sistema Único de Saúde - SUS, o planejamento da saúde, a assistência à saúde e a articulação interfederativa, e dá outras providências. 
Diario Oficial Uniao. 29 Jun 2011:1.
d Ministério da Saúde. Portaria nº 533, de 28 de março de 2012. Estabelece o elenco de medicamentos e insumos da Relação Nacional de 
Medicamentos Essenciais (RENAME) no âmbito do Sistema Único de Saúde (SUS). Diario Oficial Uniao. 29 Mar 2012.
e Torres IDC. Judicialização do acesso a medicamentos no Brasil: uma revisão sistemática [MA dissertation]. Salvador: Universidade Federal 
da Bahia; 2013.
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to chapter of the International Classification of 
Diseases – ICD-10), and medical document (prescrip-
tion and/or medical report). Statistical analyses were 
performed using R project version 2.14.1 and OpenEpi 
version 3.01 software.
Ethical aspects and confidentiality of the study were 
guaranteed. This study was a part of the “Impacto 
das ações judiciais na política nacional de assistência 
farmacêutica: gestão da clínica e medicalização da 
justiça” (Impact of lawsuits on the national pharmaceu-
tical care policy: clinical management and the medi-
calization of justice),f and the “Avaliação de cober-
tura, acesso e qualidade da assistência farmacêutica, 
garantidos pelas decisões judiciais em Minas Gerais” 
(Evaluation of the coverage, access, and quality of 
pharmaceutical care, guaranteed by the decisions of the 
courts in the State of Minas Gerais). The project was 
approved by the Ethics Committee of Universidade 
Federal de Minas Gerais (Opinion of the ETIC 
292/08, dated September 24, 2008).
RESULTS
Table 1 shows the distribution of the proportion of 
injunction motions granted in the specified course 
of time, according to the procedural variables, 
judicial representation, type of claim, defendant, 
and court in which the claim was filed. Out of the 
5,072 injunction motions selected, 4,052 (79.9%) 
were fully granted and 132 (2.6%) were partially 
granted, totaling 4,184 (82.5%). By excluding the 
initial years (1999-2002) because of less occurrence, 
the granting of injunctions varied from 95.8% in 2004 
to 76.9% in 2008, considering that the defendant could 
seek to reverse the decision by filing an appeal with the 
court thereafter. Table 1 shows that by 2003, the appeals 
did not result in suspension and in 2007 – the year with 
the highest number of suspended injunctions – approxi-
mately 10.0% of the granted motions in the first instance 
were reversed by the Court. Although, the data analyzed 
show the number of suspended injunctions, but do not 
indicate the number of appeals filed thereafter.
Table 2 shows the proportion of granted injunctions in 
cases with and without representation by legal counsel. 
All cases without legal representation were found in 
ordinary lawsuits, representing 14.4% present in this 
type of lawsuit. The ability to appeal the judiciary inde-
pendent of having an attorney is an exception in the 
Brazilian legal system, established in Article 9 of Law 
9,099/95 as well as in Article 10 of Law 10,259/2001. 
In cases where legal representation was involved, the 
proportion of acceptance was above 80.0%, more than 
the lawsuits filed without legal representation, which 
did not exceed 66.9% of the approvals. Despite lower 
acceptance rates, injunctions petitioned without the aid 
of a legal counsel, where they were granted, were in 
most cases confirmed after appeal. The cases in which 
there was legal representation, petitions made by public 
defenders achieved greater success (86.9% granted) 
and the acceptance rate of the injunctions requested 
by the center for legal assistance (84.6%) exceeded 
the motions moved by private attorneys (82.7%). The 
granting of injunctions filed in public civil actions 
(89.1%) was superior to those recorded for ordinary 
lawsuits (82.8%) and writs of mandamus (80.1%). 
However, the suspension of the injunctions in public 
civil action was 3.1% higher than that in ordinary 
actions, and 6.4% higher when compared with the 
writs of mandamus. The Federal Courts granted only 
68.6% of the injunctions, whereas the State Courts 
granted 84.8%.
Table 3 shows the time required for a decision on 
a motion for injunction in the first instance. Out of 
5,072 injunction motions, 48.2% were decided within a 
week and 70.0% within 30 days. The time between the 
date of the motion and decision interfered in the results 
of the injunction with proportionately greater accep-
tance for motions granted in very short period of time.
Although there were 6,237 diagnoses in total, covering 
450 different diseases, most cases (85.9%) reported only 
one diagnosis, varying from one to twelve. As seen in 
Table 4, digestive system diseases and neoplasms showed 
a high rate of occurrence (over 87.0%) and diseases of 
the nervous system, mental and behavioral disorders, 
and diseases of the skin and subcutaneous tissue received 
granting below 78.6% and also showed a high proportion 
of suspended injunctions (10.9%). However, there was a 
similar proportion of suspended injunctions in the diseases 
related to blood and blood-forming organs as well as in 
some immune disorders (n = 48) that obtained 98.0% of 
acceptance. The diseases in Chapter XX of the ICD-10, 
referring to the external causes of morbidity and mortality 
(V01 to Y98), were not claimed. There was no significant 
difference between the approval process of cases involving 
just one disease and those with multiple illnesses.
The comparison of acceptance proportion from the area 
of filing (capital or inland) indicated greater accep-
tance in the counties of the capital. A difference in 
acceptance rates was also observed in different judicial 
sectors.g The analysis from the judicial sectors showed 
20.8% variation among sectors, with Uberlândia 
recording the lowest percentage of acceptance (72.6% 
f Ministério da Ciência e Tecnologia; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Ministério da Saúde. Edital MCT/
CNPq/MS-SCTIE-DECIT/CT-Saúde 33/2007. Brasília (DF); 2007.
g O setor judiciário é uma divisão administrativa que consiste no agrupamento de comarcas de uma mesma região. Tribunal de Justiça de 
Minas Gerais [cited 2014 Mar 30]. Available from: http://tj-mg.justica.inf.br
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of 489 injunctions) and Divinópolis with the highest 
percentage of acceptance (93.4% of 274 injunctions).
Only one drug had been suits filed against in 
68.9% of motions, while in 96.1% of cases, up to eight 
were filed suit against. A single case had up to 27 drugs 
filed suit against. Ultimately, 9,932 medicines repre-
senting 699 different drugs were recorded. The medi-
cines with the highest numbers of lawsuits filed against 
were adalimumab (362, 83.7% of acceptance), etanercept 
(289, 77.2% of acceptance), and suporte nutricional 
(nutritional support – 237, 77.2% of acceptance). The 
drugs paroxetine (31), somatropin (26), and ferrous 
sulfate (19) received 100% acceptance. Escitalopram (28), 
sodium diclofenac (23), and nortriptyline (18) received 
less than 54.0% of the suits accepted. The anatomical 
group P (antiparasitic products, insecticides, and repel-
lents) had the lowest rate of acceptance (71.4%), but in 
none of the cases were the injunctions for this group of 
drugs suspended. The anatomical group H (systemic 
hormonal preparations, excluding sexual hormones and 
insulin) was not surpassed and had 85.7% of injunc-
tion motions granted preliminary. The presence of other 
items, along with drug petitions did not significantly 
alter the proportion of acceptances; however, they were 
11.7% higher when the prescription was attached to the 
motion (n = 4,719), 5.6% higher with medical report 
attached (n = 4,051), and 2.7% higher in motions with a 
Table 1. Annual distribution of granted injunctions. Minas Gerais, Southeastern Brazil, 1999-2009.
Year
Motion Granted Partially granted Total Suspended
N n % n % n % n %
1999a 2 2 100.0 0 0.0 2 100.0 0 0.0
2000 8 6 75.0 0 0.0 6 75.0 0 0.0
2001 3 3 100.0 0 0.0 3 100.0 0 0.0
2002 6 5 83.3 0 0.0 5 83.3 0 0.0
2003 49 41 83.7 0 0.0 41 83.7 0 0.0
2004 121 115 95.0 1 0.8 116 95.8 4 3.4
2005 368 337 91.6 5 1.4 342 93.0 9 2.6
2006 770 669 86.9 16 2.1 685 89.0 39 5.7
2007 1,231 987 80.2 51 4.1 1,038 84.3 97 9.3
2008 1,534 1,138 74.2 41 2.7 1,179 76.9 100 8.5
2009b 980 749 76.4 18 1.8 767 78.2 20 2.6
Total 5,072 4,052 79.9 132 2.6 4,184 82.5 271 5.3
a October to December.
b January to October.
Table 2. Distribution of granting according to procedural variables. Minas Gerais, Southeastern Brazil, 1999-2009.
Procedural variable
Motion Granted Partially granted Total Suspended
N n % n % n % n %
Legal representative of the beneficiary
Legal attorney 2,807 2,273 81.0 48 1.7 2,321 82.7 162 7.0
Public defender 1,175 971 82.6 50 4.3 1,021 86.9 73 7.1
Center for legal Assistance 188 151 80.3 8 4.3 159 84.6 9 5.7
Without representation 511 324 63.4 18 3.5 342 66.9 4 1.1
Not informed 391 333 85.1 8 2.1 341 87.2 23 6.7
Claim filed
Public civil action 284 242 85.2 11 3.9 253 89.1 26 10.3
Ordinary action 3,312 2,640 79.7 103 3.1 2,743 82.8 198 7.2
Writ of mandamus 1,443 1,139 78.9 18 1.2 1,157 80.1 45 3.9
Other 33 31 93.9 0 0.0 31 93.9 0 0.0
Defendant
State only 3,528 2,890 81.9 72 2.0 2,962 83.9 209 7.1
More than one defendant 1,544 1,162 75.3 60 3.9 1,222 79.2 62 5.1
Filing court
Federal 707 460 65.1 25 3.5 485 68.6 8 1.1
State 4,365 3,592 82.3 107 2.5 3,699 84.8 263 6.0
Total 5,072 4,052 79.9 132 2.6 4,184 82.5 271 5.3
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single drug. Among the drugs litigated against, 54.5% are 
standardized in the RENAME 2013 list of drugs, with 
the granting of injunctions in 81.1% of the cases. This 
finding did not differ significantly relative to drugs not 
listed in the RENAME.
DISCUSSION
Among all cases with injunctions, 4,184 out of 
5,072 cases were granted. Granting varied from 
95.8% in 2004 to 76.9% in 2008. The result of the 
injunctions varied according to the type of claim filed, 
with higher acceptance of public civil actions, and 
lower acceptance of cases with writ of Mandamus. 
Where there was legal representation, acceptance 
exceeded up to 80.0% and in cases without represen-
tation, it did not exceed more than 66.9%. The court 
also led to different results for injunction motions. 
Digestive system diseases and neoplasms showed 
up to 87.0% granting, while diseases of the nervous 
system, mental and behavioral disorders, and diseases 
of the skin and subcutaneous tissue, received granting 
less than 78.6% times and showed a high proportion 
of suspended injunctions (10.9%). As for the drugs, 
some were granted in all opportunities and others in 
only half of the cases.
The proportion of motions granted, which are verified 
in this study (82.5%), was below the results achieved 
by other studies because the literature does not report 
approval percentage of less than 90.0%, and in some 
cases, it reports 100% approval.1,8,9,11 Data referring 
to the results of injunction motions indicate that the 
development of the phenomenon and the subsequent 
maturing of discussions resulted in a stricter judi-
ciary – in Minas Gerais, between 2004 and 2008, the 
proportion of motions granted dropped from 95.8% to 
76.9%, and the proportion of injunctions suspended 
after appeals filed increased. This maturing process 
was accompanied by a consensus on the need to create 
focused interagency structures in order to provide tech-
nical assistance to the magistrates, which, in turn, could 
constitute the basis for greater judicial rigor, pursuant to 
Recommendation 31 of the National Council of Justice 
(CNJ).h However, one still needs to perform specific 
tests to check whether the proportional decrease in the 
deferrals was the result of greater rigor, and if it was, 
would there be a relationship between greater rigor and 
imposition of more secure and cost-effective benefits.
In the case of Minas Gerais, the CNJ’s recommenda-
tion encouraged the creation, in December 2010, of 
the State Executive Committee for Health,i which, 
in turn, developed partnership between the Court of 
Minas Gerais and the Center for Health Technology 
Assessment of UFMG’s Hospital das Clínicas. Since 
2010, this partnership has provided the magistrates 
the technical documentation to assist them in their 
decisions when assessing clinical issues presented in 
lawsuits involving health care. In 2014, the partnership 
also began to assist in actions involving supplementary 
health care.j Since the database of this study contained 
lawsuits from 1999 to 2009, the introduction of expert 
opinion in the evaluation of the actions did not contem-
plate a sensitive variable.
The time required to grant the injunctions is an impor-
tant indicator to portray the extent to which health care 
claims are treated as emergencies by the judiciary. This 
study reinforces the results achieved by other studies 
by showing that, in most cases, the approval occurred 
within 30 days, and a considerable proportion of the 
motions were granted within a week.8,9,k However, 
we still need to investigate whether the perception of 
urgent health care assessed by the judiciary is supported 
by scientific standards, especially after the creation 
of institutional technical support structures. As for 
the relationship between the time and proportion of 
motions attended to, those that were decided in lesser 
Table 3. Distribution of the granting of injunctions according to the time for decision. Minas Gerais, Southeastern Brazil, 1999-2009.
Time
Motion Granted Partially granted Total
n % n % n % n %
Up to 1 day 266 5.2 250 93.9 2 0.8 252 94.7
Up to 1 week 2,180 43.0 1,950 89.4 3 0.1 1,953 89.5
Up to 30 days 1,054 20.8 894 84.9 3 0.2 897 85.1
Over 30 days 978 19.3 772 78.9 4 0.4 776 79.3
Date unknown 594 11.7 186 31.2 120 20.3 306 51.5
Total 5,072 100.0 4,052 100.0 132 100.0 4,184 100.0
h Recomendação nº 31 de 30 de março de 2010. Recomenda aos Tribunais a adoção de medidas visando a melhor subsidiar os magistrados e demais 
operadores do direito, para assegurar maior eficiência na solução das demandas judiciais envolvendo a assistência à saúde. DJ. 7 Abr 2010:4-6.
i Tribunal de Justiça de Minas Gerais. Magistrado do TJMG integra Fórum Nacional do Judiciário para a Saúde. Minas Gerais; 2013 [cited 
2014 Mar 30]. Available from: http://tj-mg.justica.inf.br/noticia/2013/10/magistrado-tjmg-integra-forum-nacional-judiciario-saude
j Tribunal de Justiça de Minas Gerais. Convênio vai orientar magistrados nas ações envolvendo saúde. Minas Gerais; 2014 [cited 2014 Mar 30]. 
Available from: http://www.tjmg.jus.br/portal/imprensa/noticias/convenio-vai-orientar-magistrados-nas-acoes-envolvendo-saude-1.htm#.Uzi0mqhdU0g
k Camargo IA. Análise das demandas judiciais para o tratamento da artrite reumatoíde no Estado de São Paulo [MA dissertation]. Sorocaba: 
Universidade de Sorocaba; 2011.
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periods showed the highest proportion of approvals. 
This finding indicates the need to verify the existence 
of the association between the time of acceptance and 
the effective provision of technical assistance.
The prevalence of chronic diseases observed is similar 
to the findings of other studies.8.13 There was no unifor-
mity of approval when cases were analyzed on the basis 
of the diagnosed diseases. The trend indicates that the 
court’s decision is sensitive to the potential risk to the 
patient. The need for quicker treatment in order to 
achieve the best treatment or the possibility of a cure 
may have influenced the formation of an emergency; 
the diseases related to blood and blood-forming organs 
were superior in their approvals to cases involving 
chronic diseases or long-term treatments, such as skin 
diseases and mental disorders. It is conjectured that 
the financial impact of treatment may have touched the 
judges as well, since diseases, which initially do not 
involve emergencies, but then require very expensive 
treatment at later stages, showed approvals similar to 
those with imminent risk.
The comparison of approval proportions based on 
the type of action indicated a higher proportion of 
the granting of injunctions in public civil actions, 
contrary to expectations. Valle & Camargo10 argue 
that the statements given at the public hearing held in 
Table 4. Distribution of the results of injunctions related to disease classified by WHO/ICD-10. Minas Gerais, Southeastern 
Brazil, 1999-2009.
Disease according to chapter of ICD-10
Motion Granted
Partially 
granted
Total Suspended 
N n % n % n % n %
D50-D89 III Diseases of the blood and 
blood-forming organs, and certain immune 
disorders
48 44 91.7 3 6.3 47 98.0 5 10.4
XVI P00-P96 Certain conditions originating 
in the perinatal period
14 13 92.9 0 0.0 13 92.9 0 0.0
XI K00-K93 Diseases of the digestive system 323 284 87.9 5 1.5 289 89.4 8 2.5
XVII Q00-Q99 Congenital malformations, 
deformations and chromosomal abnormalities
60 50 83.3 3 5.0 53 88.3 2 3.3
II C00-D48 Neoplasms [Tumors] 495 428 86.5 3 0.6 431 87.1 30 6.1
XIX S00-T98 Injury, poisoning, and certain 
other consequences of external causes
53 39 73.6 7 13.2 46 86.8 9 17.0
X J00-J99 Diseases of the respiratory system 234 190 81.2 12 5.1 202 86.3 15 6.4
XIV N00-N99 Diseases of the genitourinary 
system
151 117 77.5 12 7.9 129 85.4 7 4.6
XV O00-O99 Pregnancy, childbirth, and 
puerperium
13 11 84.6 0 0.0 11 84.6 0 0.0
IX I00-I99 Diseases of the circulatory system 626 481 76.8 38 6.1 519 82.9 23 3.7
III A00-B99 Certain infectious and parasitic 
diseases
174 142 81.6 2 1.1 144 82.7 11 6.3
IV E00-E90 Endocrine, nutritional, and 
metabolic diseases
680 543 79.9 19 2.8 562 82.7 35 5.1
XIII M00-M99 Diseases of the 
musculoskeletal system and connective 
tissue
887 714 80.5 18 2.0 732 82.5 62 7.0
VII H00-H59 Diseases of the eye and 
adnexa
139 111 79.9 1 0.7 112 80.6 6 4.3
VI G00-G99 Diseases of the nervous system 407 293 72.0 27 6.6 320 78.6 10 2.5
V F00-F99 Mental and behavioral disorders 481 363 75.5 9 1.9 372 77.4 20 4.2
XVIII R00-R99 Symptoms, signs, and 
abnormal clinical and laboratory findings 
not classified elsewhere
48 36 75.0 1 2.1 37 77.1 4 8.3
XXI Z00-Z99 Factors influencing health 
condition and contact with health services
30 23 76.7 0 0.0 23 76.7 0 0.0
VIII H60-H96 Diseases of the ear and 
mastoid process
4 3 75.0 0 0.0 3 75.0 0 0.0
XII L00-L99 Diseases of the skin and 
subcutaneous tissue
156 113 72.4 2 1.3 115 73.7 17 10.9
CID not specified or invalid 931 931 76.7 42 3.2 973 79.9 68 5.6
Total 6,237 4,929 79.0 204 3.3 5,133 82.3 333 5.3
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2009 in the Supreme Court indicate a pattern by the 
judiciary toward the greater acceptance of individual 
claims, given that the financial impact of the judicial 
action would not be as evident as that in class actions. 
Even with 10.0% of the revoked injunctions, the public 
civil actions remained ahead of other types of actions 
in terms of acceptance proportion. However, in some 
cases, public civil actions are managed to ensure indi-
vidual rights, and it would therefore not be appropriate 
to assume them to always be collective. As for this 
aspect, in spite of Law 7,347/1985 (regulates the public 
civil action), establishing that it should handle cases 
involving collective or diffuse interests, the courts, 
including the High Court of Justice (precedent: REsp 
931,513/RS, REsp 819,010/SP and AgRg no REsp 
1328270/MG), consolidated the possibility of using the 
action in drug claims for a single citizen, particularly in 
cases of “protection by the court of hyper-vulnerable 
interests” (REsp 931,513/RS).
The discrepancy in approval observed from the compar-
ison between the lawsuits filed in Federal and State 
Courts indicate the need for studies that seek to iden-
tify, for each justice (State and Federal), the differences 
in training judges, especially with regard to health law 
or which propose to evaluate the distinctions related 
to the quality of the institutional structures created to 
provide technical support to the judges.
The verification of the proportion of approvals based 
on the types of representation and the most successful 
motions made in proceedings with professional repre-
sentation ratify the fact that the motions filed by lawyers 
favor approval. This situation questions the mechanisms 
established to facilitate access to justice, regardless of 
the representation by the legal professional given that, 
in principle, the use of such paths could not interfere 
with the patient’s chance of success, especially in cases 
involving health emergencies. In this sense, one should 
investigate the specific aspects of the legal representa-
tive’s performance that can interfere with the granting 
as well as clarify the reason or the reduced rate of 
successful cases with judicial representation with the 
courts of appeal.
Pepe et al8 evaluated the decisions of court injunctions 
in the State of Rio de Janeiro, Southeastern Brazil. The 
authors suggested an almost absolute trend of accep-
tance in the actions that petitioned for drugs. In this 
study, we found a maximum approval of 85.7%, with 
less than 70.0% acceptance near or distant from an 
absolute granting for the same. Considering some 
diseases individually, approval is almost absolute; as 
is the case of diseases related to the blood and blood-
forming organs as well as some immune disorders in 
which the proportion of granting reached 98.0%. These 
results suggest specific differences in the treatment of 
injunctions. The variation of acceptance in different 
Table 5. Requested medication according to ATC/WHO Classification. Minas Gerais, Southeastern Brazil, 1999-2009.
Anatomical level
Motion Granted Partially granted Total
Suspended by 
appeal to the 
Court
N n % n % n % n %
H – Systemic hormonal preparations, 
excluding sex hormones and insulin
328 269 82.0 12 3.7 281 85.7 17 5.2
J – General anti-infectives for systemic use 375 309 82.4 9 2.4 318 84.8 26 6.9
L – Antineoplastic and 
immunomodulating agents
1,800 1,494 83.0 23 1.3 1,517 84.3 131 7.3
B – Blood and blood-forming organs 579 444 76.7 42 7.3 486 84.0 26 4.5
R – Respiratory system 482 380 78.8 25 5.2 405 84.0 26 5.4
A – Digestive System and Metabolism 1,518 1,167 76.9 81 5.3 1,248 82.2 66 4.3
D – Dermatological Drugs 125 91 72.8 11 8.8 102 81.6 7 5.6
G – Urogenital system and sex hormones 279 214 76.7 10 3.6 224 80.3 12 4.3
V – Various 339 252 74.3 16 4.7 268 79.0 8 2.4
C – Cardiovascular system 1,467 1,003 68.4 154 10.5 115 78.9 72 4.9
N – Nervous System 1,935 1,383 71.5 115 5.9 1,498 77.4 80 4.1
S – Sense organs 215 156 72.6 4 1.9 160 74.5 6 2.8
M – Musculoskeletal System 333 213 64.0 30 9.0 243 73.0 27 8.1
P – Antiparasitic products, insecticides, 
and repellents
21 15 71.4 0 0.0 15 71.4 0 0.0
Not specified or invalid 136 89 65.4 4 2.9 93 68.3 4 2.9
Total 9,932 7,479 75.3 538 5.4 8,017 80.7 508 5.1
ATC: Anatomical Therapeutic Chemical; WHO: World Health Organization
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anatomical groups of the ATC indicates that some treat-
ments may influence the court’s decision.
We observed the exploratory character of the statistical 
method chosen to establish the differences between the 
groups. Although the number of evaluated cases was 
lower in the early years and demanded correction of 
continuity, the approach to the whole period adds repre-
sentativeness to the study of the phenomenon. Given the 
results, in-depth statistical analyses should be prepared to 
make specific comparisons and enable further knowledge 
on the elements that influence the outcome of judicial 
decisions. Important trends in the standard of judicial 
performance were observed in procedural variables 
(court of filing, legal representation, time between motion 
and decision), clinical (disease and drug), and particu-
larly with respect to the change in the performance stan-
dard in the study period. These results will allow us to 
obtain a fresh perspective of the legalization of health, 
as it is from the identification and understanding of the 
elements that determine judicial decisions that one can 
more clearly identify the extent to which judicial actions 
can help to expand the State’s capacity to meet the real 
health care needs of the population.
